- Home
- » e-Newsletters
AWP reimbursement limits down for two drugs
Pharmacy Regulation Resource, July 21, 2004
Payment limits for two drugs-the precancerous skin-lesion treatment aminolevulinic acid HCl and the fulvestrant injector for hormone receptor-positive metastatic breast cancer-are down to 85% of average wholesale price (AWP) for the remainder of 2004, according to Centers for Medicare & Medicaid Services Transmittal 90 released June 25.
Two payment limits took effect for services on January 1:
aminolevulinic acid HCl (topical), HCPCS code J7308: $111.47
fulvestrant (injection), HCPCS code J9395: $81.57
Each figure supercedes the 95% AWP limit published January 30.
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- Capturing all necessary codes for IUD insertion and removal can be challenging
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- HIPAA Q&A: Level of encryption needed for email
- OB services: Coding inside and outside of the package
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Q/A. One injection code or two?
- What does case-mix index mean to you?
- ED-to-inpatient transfers are flawed with safety gaps
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Searched